Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies
© 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation..
BACKGROUND: Activin-A is a molecule of the TGF superfamily, implicated in liver fibrosis, regeneration and stem cell differentiation. However, data on activins in liver diseases are few. We therefore studied serum levels of activin-A in chronic liver diseases. To identify the origin of activin-A, levels in the hepatic vein were also estimated.
MATERIALS AND METHODS: Nineteen controls and 162 patients participated in the study: 39 with hepatocellular carcinoma (HCC: 19 viral associated and 20 alcohol associated), 18 with chronic hepatitis C (CHC), 47 with primary biliary cirrhosis (26 PBC stage I-II and 21 stage IV), 22 with alcoholic cirrhosis (AC, hepatic vein blood available in 16), 20 with HCV cirrhosis (hepatic vein blood available in 18) and 16 patients with alcoholic fatty liver with mild to moderate fibrosis but no cirrhosis.
RESULTS: Activin-A levels were significantly increased (P < 0·001) in serum of patients with AC (median 673 pg/mL, range 449-3279), compared with either controls (149 pg/mL, 91-193) or patients with viral cirrhosis (189 pg/mL, 81-480), CHC (142 pg/mL, 65-559) PBC stage I-II (100 pg/mL, 59-597) and PBC stage IV (104 pg/mL, 81-579). Only patients with AC-associated HCC had significantly increased levels of activin-A (2403 pg/mL, 1561-7220 pg/mL). Activin-A serum levels could accurately discriminate AC from cirrhosis of other aetiologies and noncirrhotic alcoholic fatty liver with fibrosis.
CONCLUSIONS: Increased serum levels of activin-A only in patients with alcohol-related cirrhosis or HCC suggest a possible role of this molecule in the pathophysiology of AC. Further research is warranted to elucidate its role during the profibrotic process and its possible clinical applications.
| Errataetall: |
CommentIn: Eur J Clin Invest. 2012 Oct;42(10):1147; author reply 1148. - PMID 22577966 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
European journal of clinical investigation - 42(2012), 8 vom: 06. Aug., Seite 815-22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Voumvouraki, Argyro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 04.12.2012 Date Revised 18.07.2012 published: Print-Electronic CommentIn: Eur J Clin Invest. 2012 Oct;42(10):1147; author reply 1148. - PMID 22577966 Citation Status MEDLINE |
|---|
| doi: |
10.1111/j.1365-2362.2012.02647.x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM215131282 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM215131282 | ||
| 003 | DE-627 | ||
| 005 | 20231224024927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/j.1365-2362.2012.02647.x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0717.xml |
| 035 | |a (DE-627)NLM215131282 | ||
| 035 | |a (NLM)22304651 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Voumvouraki, Argyro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased serum activin-A differentiates alcoholic from cirrhosis of other aetiologies |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2012 | ||
| 500 | |a Date Revised 18.07.2012 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur J Clin Invest. 2012 Oct;42(10):1147; author reply 1148. - PMID 22577966 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2012 The Authors. European Journal of Clinical Investigation © 2012 Stichting European Society for Clinical Investigation Journal Foundation. | ||
| 520 | |a BACKGROUND: Activin-A is a molecule of the TGF superfamily, implicated in liver fibrosis, regeneration and stem cell differentiation. However, data on activins in liver diseases are few. We therefore studied serum levels of activin-A in chronic liver diseases. To identify the origin of activin-A, levels in the hepatic vein were also estimated | ||
| 520 | |a MATERIALS AND METHODS: Nineteen controls and 162 patients participated in the study: 39 with hepatocellular carcinoma (HCC: 19 viral associated and 20 alcohol associated), 18 with chronic hepatitis C (CHC), 47 with primary biliary cirrhosis (26 PBC stage I-II and 21 stage IV), 22 with alcoholic cirrhosis (AC, hepatic vein blood available in 16), 20 with HCV cirrhosis (hepatic vein blood available in 18) and 16 patients with alcoholic fatty liver with mild to moderate fibrosis but no cirrhosis | ||
| 520 | |a RESULTS: Activin-A levels were significantly increased (P < 0·001) in serum of patients with AC (median 673 pg/mL, range 449-3279), compared with either controls (149 pg/mL, 91-193) or patients with viral cirrhosis (189 pg/mL, 81-480), CHC (142 pg/mL, 65-559) PBC stage I-II (100 pg/mL, 59-597) and PBC stage IV (104 pg/mL, 81-579). Only patients with AC-associated HCC had significantly increased levels of activin-A (2403 pg/mL, 1561-7220 pg/mL). Activin-A serum levels could accurately discriminate AC from cirrhosis of other aetiologies and noncirrhotic alcoholic fatty liver with fibrosis | ||
| 520 | |a CONCLUSIONS: Increased serum levels of activin-A only in patients with alcohol-related cirrhosis or HCC suggest a possible role of this molecule in the pathophysiology of AC. Further research is warranted to elucidate its role during the profibrotic process and its possible clinical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a activin A |2 NLM | |
| 650 | 7 | |a Activins |2 NLM | |
| 650 | 7 | |a 104625-48-1 |2 NLM | |
| 700 | 1 | |a Notas, George |e verfasserin |4 aut | |
| 700 | 1 | |a Koulentaki, Mairi |e verfasserin |4 aut | |
| 700 | 1 | |a Georgiadou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Klironomos, Stefanos |e verfasserin |4 aut | |
| 700 | 1 | |a Kouroumalis, Elias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical investigation |d 1970 |g 42(2012), 8 vom: 06. Aug., Seite 815-22 |w (DE-627)NLM000003107 |x 1365-2362 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2012 |g number:8 |g day:06 |g month:08 |g pages:815-22 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2362.2012.02647.x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2012 |e 8 |b 06 |c 08 |h 815-22 | ||